Rhumbline Advisers Relmada Therapeutics, Inc. Transaction History

Rhumbline Advisers

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$2.93 - $4.94 $143 - $242	-49 Reduced 4.17%	1,125 $3,000
Q3 2023 Nov 09, 2023	SELL	$2.48 - $3.79 $5,639 - $8,618	-2,274 Reduced 65.95%	1,174 $3,000
Q2 2023 Aug 08, 2023	SELL	$2.22 - $3.54 $75,895 - $121,021	-34,187 Reduced 90.84%	3,448 $8,000
Q1 2023 May 11, 2023	BUY	$2.24 - $4.76 $2,446 - $5,197	1,092 Added 2.99%	37,635 $85,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $35.84 $607 - $10,035	280 Added 0.77%	36,543 $128,000
Q3 2022 Nov 10, 2022	BUY	$18.3 - $37.02 $51,752 - $104,692	2,828 Added 8.46%	36,263 $1.34 Million
Q2 2022 Aug 11, 2022	BUY	$16.5 - $30.34 $195,954 - $360,317	11,876 Added 55.09%	33,435 $635,000
Q1 2022 May 12, 2022	BUY	$16.72 - $26.99 $99,902 - $161,265	5,975 Added 38.34%	21,559 $582,000
Q4 2021 Feb 10, 2022	SELL	$16.93 - $26.82 $4,097 - $6,490	-242 Reduced 1.53%	15,584 $351,000
Q3 2021 Nov 12, 2021	BUY	$21.86 - $34.77 $14,711 - $23,400	673 Added 4.44%	15,826 $415,000
Q2 2021 Aug 05, 2021	SELL	$29.55 - $39.15 $36,642 - $48,546	-1,240 Reduced 7.56%	15,153 $485,000
Q1 2021 May 06, 2021	SELL	$31.52 - $39.28 $23,167 - $28,870	-735 Reduced 4.29%	16,393 $577,000
Q4 2020 Feb 10, 2021	BUY	$29.88 - $39.8 $33,764 - $44,974	1,130 Added 7.06%	17,128 $549,000
Q3 2020 Nov 12, 2020	SELL	$34.42 - $43.78 $63,504 - $80,774	-1,845 Reduced 10.34%	15,998 $602,000
Q2 2020 Aug 13, 2020	BUY	$31.59 - $49.98 $563,660 - $891,793	17,843 New	17,843 $798,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.3M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.